This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.
Join the movement
Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
Congratulations!
MEpedia has got over 30 million views as of August 2022!

Rotigotine

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Rotigotine is a dopamine agonist used for Parkinson's disease and restless leg syndrome (RLS) which is available only as a slow-release transdermal patch applied to the skin.[1][2] Rotigotine is also sold under the brand name Neupro.[1][3] Rotigotine is in the same class of drugs as ropinirole and pramipexole.[4]

Theory[edit | edit source]

Evidence[edit | edit source]

No clinicial trials have yet been carried out of rotigotine for patients with ME/CFS.

A single study of rotigotine for fibromyalgia had high dropout rates for both the drug and placebo, but did not appear to show a significant improvement in pain or other fibromyalgia symptoms at doses of 4mg or 8mg.[4][5]

There is inconsistent evidence of the effect of rotigotine on fatigue in Parkinson's disease.[6][7]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Notable studies[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]


References[edit | edit source]